AFTER 1st_BOIF
> ATTENDEES
> INVESTORS
> PRESENTERS
> SPONSORS​
> SUPPORTERS​

20-minute presenterS

APHAIA Pharma AG

Aphaia Pharma is a clinical-stage biopharma company harnessing precision-targeted drug formulations to restore endogenous endocrine and neuroendocrine balance for the treatment of obesity and associated metabolic diseases.

www.aphaiapharma.com

Astrizi Bio

Astrizi Bio is a preclinical stage biopharmaceutical company developing innovative, orally available, disease modifying therapeutics for obesity and Parkinson's disease.

www.astrizi.com

Clywedog Therapeutics Inc

Profile to be announced...

Halia Therapeutics

Halia is developing a pipeline of therapeutics targeting the RAB10 pathway, with LRRK2 upstream and NEK7 downstream, directly addressing the NLRP3 inflammasome. These targets aim to reduce inflammation and reset the inflammatory pathway. Halia is in the early stages of clinical trials to test the safety and efficacy of this approach in patients. Pre-clinical studies have shown promising results in suppressing inflammatory signals across various organs, from the brain to the skin.​

www.haliatx.com

10-minute presenterS

Adipo Therapeutics, LLC

Adipo Therapeutics mission is to advance the treatment of Obesity by increasing resting metabolism through inducing the browning of subcutaneous white fat to healthier, energy buring fat.​

www.adipotherapeutics.com

​Biophytis
[EPA: ALBPS]

Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases.​

www.biophytis.com

Bloom Science, Inc.

Bloom Science is redefining medicine by creating innovative therapies that harness the body’s natural metabolic and neurological pathways. Inspired by the therapeutic benefits of the ketogenic diet, Bloom’s approach targets multiple mechanisms simultaneously to provide safer, more effective solutions for obesity, Dravet syndrome, ALS, and other complex conditions.

Our lead program, BL-001, is a live biotherapeutic product reverse engineered to replicate the ketogenic diet’s clinical efficacy. BL-001 has demonstrated proof of mechanism and has been observed to be safe and tolerable, with Bloom planning Phase 2 clinical trials in both obesity and Dravet syndrome.

The IrisRx™ discovery platform powers Bloom’s pipeline by integrating cutting-edge science and a proprietary knowledgebase. This platform enables the development of novel, multi-pathway therapeutics through gut commensal microbes and synthetic biology, delivering innovative treatments with broad therapeutic potential. Backed by top-tier investors and a team of industry veterans, Bloom Science is advancing a deep pipeline to transform patient care and create lasting clinical impact.

www.bloomscience.com

Canary Cure Therapeutics Inc. 

Beyond Incretins: Canary Cure's CCT-217 Dual siRNA Gene Silencing Therapy Offers a Novel Approach to Obesity with Superior Fat Loss, Increase in Lean Muscle and Improved Body Composition:

Canary Cure Biotechnologies, a late stage pre-clinical company, is tackling the growing obesity and diabetes crisis with CCT-217, a first-in-class dual siRNA gene precision therapy.  Our pioneering approach offers a significant advancement over existing treatments, focusing on precise targeting and durable effects.   

Studies show CCT-217's innovative mechanism of action reprograms white fat cells leading to more metabolically active brown fat, leading to a remarkable 25% increase in lean muscle mass while simultaneously reducing fat mass and increasing resting energy expenditure.  This not only promotes weight loss but also improves metabolic function and overall health.   

What sets CCT-217 apart is its unique ability to preserve lean body mass, a crucial factor often overlooked by current therapies.  This proactive approach ensures healthier and more sustainable weight loss, addressing a critical unmet need in the obesity treatment landscape.   

Furthermore, CCT-217's potential for twice-annual, self-administered dosing offers unparalleled convenience and patient compliance.  This long-acting profile, combined with its targeted action and impressive efficacy, positions CCT-217 as a game-changer in the $200 Billion ( by 2030) Obesity treatment market.  

Invest in Canary Cure's therapeutic development and support our mission to revolutionize metabolic disease management with CCT-217, a breakthrough therapy poised to redefine the future of obesity care.

www.canarycure.com

Lipidio Pharmaceuticals, Inc.

Lipidio is a clinical stage company focused on developing a unique approach to treating systemic metabolic diseases by targeting the neuro-endocrine properties of skin.

Our lead asset, GDD3898, is a Phase 2-ready obesity drug which acts by increasing energy expenditure with preclinical efficacy equivalent to GLP-1 agonists but without muscle loss.

www.lipidiopharma.com

MelliCell, Inc.

MelliCell makes fat that people want for pioneering next-gen therapeutics for obesity and chronic disease.

www.mellicell.com

Myracle Therapeutics, Inc.

Myracle Therapeutics is a preclinical stage company developing small molecules against novel targets in adipocytes to treat obesity and metabolic related diseases. Our lead program targets an enzyme that regulates intracellular signaling in adipocytes, resulting in metabolic reprogramming of adipose for durable weight loss and metabolic health.  Our first-in-class MoA is complimentary to GLP1+ agents. Consensus estimate market size for non-GLP1 based obesity medicines is $30B by 2035.

Metabolically healthy adipose is essential for a metabolically healthy human. Insulin resistance in adipose, due to inflammation and subsequent fibrosis, leads to systemic insulin resistance. Our lead program switches adipose phenotype from toxic to healthy, reducing inflammation and insulin resistance, and increasing energy expenditure. This new paradigm in weight loss goes beyond appetite reduction to metabolic remodeling, resulting in sustainable weight loss and metabolic health.

www.myracletx.com

Olio Labs

Olio Labs is developing a new computational and experimental approach to design best-in-class combination drug therapies.​

www.oliolabs.co

Orion Biotechnology

Orion Biotechnology is GPCR company focused on novel metabolic targets.

Orion’s lead program targets GPR75, a novel next generation obesity target for quality weight loss with the preservation of lean mass. Orion is advancing two approaches against GPR75, which include an orally bioavailable compound to be clinic ready in 2025.

We continue to build a portfolio of next generation targets using our core capabilities.  Our discovery campaigns focus on high-value metabolic targets, which include but not limited to GIPR and Amylin.

www.orionbiotechnology.com

Resalis Therapeutics

Resalis Therapeutics is a biotechnology company based in Turin, Italy, founded in 2021. It specializes in developing RNA-based therapies to treat metabolic disorders, focusing on obesity and metabolic-associated fatty liver disease (MAFLD). Its lead drug candidate, RES-010, targets the non-coding RNA miR-22 to achieve durable weight loss and reduce liver fat. Supported by significant investments, including from Sunstone Life Science Ventures and Claris Ventures, Resalis is advancing towards clinical trials, aiming to deliver disease-modifying solutions in metabolic health.​

www.resalistherapeutics.com

virtual showcases

Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical: Revolutionizing Inflammatory and Metabolic Care.

Sen-Jam Pharmaceutical is pioneering a revolutionary approach to inflammatory and metabolic disorders with our proprietary PAIR (Pleiotropic Anti-Inflammatory Remedies) technology. By working with the body’s innate wisdom, our precision remedies modulate inflammation at its source, addressing systemic risks linked to chronic conditions like obesity, metabolic dysfunction, and autoimmune diseases—all without suppressing the immune system. We are leading the next evolution in healthcare, delivering innovative treatments that enhance vitality, extend health spans, and redefine how the world heals.

What Problem Are We Solving?

Chronic inflammation is a silent driver of countless diseases, from metabolic disorders like obesity and MASLD to autoimmune and everyday health challenges. Yet, current treatments often suppress the immune system, creating new risks. The world needs a smarter, safer way to address inflammation and metabolic dysfunction at their core without compromising overall health. Sen-Jam Pharmaceutical’s breakthrough PAIR technology is designed to solve this urgent problem, offering precision anti-inflammatory and metabolic remedies that preserve vitality, support weight management, enhance productivity, and improve lives.

What’s Our Unfair Advantage?

Sen-Jam Pharmaceutical’s “unfair advantage” lies in the exceptional caliber of our team and the groundbreaking potential of our proprietary PAIR technology. Our scientific advisors, with decades of experience at world-renowned institutions like the Mayo Clinic, Boston Medical Center, Harvard School of Public Health, and Cornell University, are Ivy League-published experts solving the world’s toughest health challenges. This unparalleled expertise, combined with our precision-driven approach to inflammatory and metabolic care, positions Sen-Jam to disrupt the market and emerge as a transformative unicorn in healthcare.

www.sen-jam.com